Ocular Therapeutix develops eye treatments, including AXPAXLI, an investigational drug in trials for eye diseases, and sells DEXTENZA. It last closed at $6.02 on Nov 17, up 0.17% on the day. OCUL reports earnings on Thu, Feb 4, 2027. The average 12-month price target from 4 analysts is $20.75 (+244.7% from the last close), with a high of $28.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $800K, the largest $612K.
Each firm's latest rating on OCUL in the past 90 days
Average 12-month target
$20.75
▲ 244.7% upside
Based on 4 analysts who set a price target on OCUL in the past 90 days. The average target is $20.75, with a high of $28.00 and a low of $14.00, compared with the last close of $6.02.
Highest target$28.00
Average target$20.75
Lowest target$14.00
Latest rating changes
HC Wainwright & Co.Target raised
Nov 10Buy$25 → $28
NeedhamReiterated
Oct 19Buy$18
UBSInitiated
Oct 12Buy$14
NeedhamReiterated
Sep 29Buy$18
Chardan CapitalMaintained
Sep 16Buy$23
Date
Firm
Action
Rating
Price target
Nov 10
HC Wainwright & Co.
Target raised
Buy
$25 → $28
Oct 19
Needham
Reiterated
Buy
$18
Oct 12
UBS
Initiated
Buy
$14
Sep 29
Needham
Reiterated
Buy
$18
Sep 16
Chardan Capital
Maintained
Buy
$23
Loading…
Technical Analysis
OCUL · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 10% below its 20 day and 29% below its 50 day average. It is 47% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Oct 19) at $6.00, and the nearest resistance the Pivot at $6.03.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.4%/day
Key levels
$16.4452 week high+173.1%
$8.87200 day average+47.3%
$8.79100 day average+46.0%
$7.7950 day average+29.4%
$7.24Swing high (Nov 5)+20.3%
$6.6420 day average+10.3%
$6.26Pivot R1+4.0%
$6.03Pivot+0.2%
$6.02Last close
$6.00Swing low (Oct 19)−0.3%
$5.8052 week low−3.7%
$5.79Pivot S1−3.8%
Indicators
RSI (14)
35.67
Weak, oversold below 30
Neutral
MACD
-0.40
Below its signal line
Bearish
Stochastic
10.2
Near the bottom of its range
Oversold
ADX (14)
42.0
Strong downtrend
Williams %R
-87.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-166.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.7%
Change over 10 sessions
Bearish
ATR (14)
$0.44
Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 18.7%/day
Key levels
$16.4452 week high+173.1%
$8.87200 day average+47.3%
$8.79100 day average+46.0%
$7.7950 day average+29.4%
$7.24Swing high (Nov 5)+20.3%
$6.6420 day average+10.3%
$6.26Pivot R1+4.0%
$6.03Pivot+0.2%
$6.02Last close
$6.00Swing low (Oct 19)−0.3%
$5.8052 week low−3.7%
$5.79Pivot S1−3.8%
Indicators
RSI (14)
35.36
Weak, oversold below 30
Neutral
MACD
-0.88
Below its signal line
Bearish
Stochastic
5.9
Near the bottom of its range
Oversold
ADX (14)
18.4
No clear trend
Williams %R
-96.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-119.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−42.6%
Change over 10 sessions
Bearish
ATR (14)
$1.13
Typical daily range, 18.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for OCUL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OCUL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow OCUL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OCUL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCUL is in one of them and how their past OCUL trades turned out.
Ocular Therapeutix is a biopharmaceutical company based in Bedford, Massachusetts, that develops and sells treatments for eye conditions. Its lead investigational product, AXPAXLI, is a drug delivered into the eye through a gel that dissolves over time, and it is being tested for wet macular degeneration and diabetic retinal disease. The company also sells DEXTENZA, an FDA-approved insert used to treat eye pain and inflammation after surgery and itching from allergic conjunctivitis.